While AT/RT-MYC and AT/RT-TYR show differences in differentially regulated genes, tumor location, and median patient age, they display some common features as well.51,53 Notably, pathways associated with the immune response and genes related to BMP signaling (BMP4, BAMB1, GDF5, FOXC1) and mesenchymal differentiation (SERPINF1, CLDN10, FBN2, MSX1, PDGFRB) are enriched in both AT/RT-MYC and AT/RT-TYR.51,53,57 Overexpression of tyrosinase (TYR), which is not expressed in AT/RT-SHH or AT/RT-MYC, has been established as the most distinguishable marker of the AT/RT-TYR subgroup. This evidence concerns the gene TYR and neoplasm.